Loading...

Frost, Patrick J

Title(s)Associate Adjunct Professor, Medicine
Phone310-268-3247
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    ShEEP Request for Small Animal Magnetic Resonance Imaging System
    VA IS1BX005024Sep 1, 2019 - Aug 31, 2020
    Role: Principal Investigator
    Targeting the in Vivo Hypoxic Microenvironment of Multiple Myeloma as an Anti-Tumor Strategy
    VA I01BX004280Jul 1, 2019 - Jun 30, 2023
    Role: Principal Investigator
    Acquisition of a SOPHIA G8 PET/CT Animal Imager
    VA IS1BX003089Apr 1, 2015 - Sep 30, 2015
    Role: Principal Investigator
    Effects of mTOR inhibitors on MM tumors
    VA I01BX001532Oct 1, 2011 - Sep 30, 2015
    Role: Principal Investigator
    Effects of mTOR inhibitors on multiple myeloma tumors
    NIH/NCI K01CA111623Aug 1, 2005 - Jul 31, 2012
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Vega MI, Shi Y, Frost P, Huerta-Yepez S, Antonio-Andres G, Hernandez-Pando R, Lee J, Jung ME, Gera JF, Lichtenstein A. A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity. Mol Cancer Ther. 2019 10; 18(10):1822-1831. PMID: 31395691.
      View in: PubMed
    2. Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet ML, Jung ME, Gera J, Lichtenstein A. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells. Cancer Res. 2016 10 01; 76(19):5822-5831. PMID: 27530328.
      View in: PubMed
    3. Hoang B, Shi Y, Frost PJ, Mysore V, Bardeleben C, Lichtenstein A. SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism. Mol Cancer Res. 2016 Apr; 14(4):397-407. PMID: 26869290.
      View in: PubMed
    4. Mysore VS, Szablowski J, Dervan PB, Frost PJ. A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity. Mol Cancer Res. 2016 Mar; 14(3):253-66. PMID: 26801054.
      View in: PubMed
    5. Yang Y, Bardeleben C, Frost P, Hoang B, Shi Y, Finn R, Gera J, Lichtenstein A. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Genes Cancer. 2014 Nov; 5(11-12):407-19. PMID: 25568666.
      View in: PubMed
    6. Shi Y, Frost P, Hoang B, Yang Y, Bardeleben C, Gera J, Lichtenstein A. MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses. PLoS One. 2014; 9(4):e94011. PMID: 24714040.
      View in: PubMed
    7. Frost P, Berlanger E, Mysore V, Hoang B, Shi Y, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. J Oncol. 2013; 2013:897025. PMID: 23533410.
      View in: PubMed
    8. Hoang B, Benavides A, Shi Y, Yang Y, Frost P, Gera J, Lichtenstein A. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J Biol Chem. 2012 Jun 22; 287(26):21796-805. PMID: 22556409.
      View in: PubMed
    9. Shi Y, Frost P, Hoang B, Benavides A, Gera J, Lichtenstein A. IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1. J Biol Chem. 2011 Jan 07; 286(1):67-78. PMID: 20974848.
      View in: PubMed
    10. Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, Cappia S, Guglielmelli T, Gera J, Lichtenstein A. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood. 2010 Nov 25; 116(22):4560-8. PMID: 20686120.
      View in: PubMed
    11. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther. 2009 Jul; 8(7):1974-84. PMID: 19509276.
      View in: PubMed
    12. Frost P, Shi Y, Hoang B, Gera J, Lichtenstein A. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Mol Cancer Ther. 2009 Jan; 8(1):83-93. PMID: 19139116.
      View in: PubMed
    13. Shi Y, Frost PJ, Hoang BQ, Benavides A, Sharma S, Gera JF, Lichtenstein AK. IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. Cancer Res. 2008 Dec 15; 68(24):10215-22. PMID: 19074889.
      View in: PubMed
    14. Frost P, Shi Y, Hoang B, Lichtenstein A. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene. 2007 Apr 05; 26(16):2255-62. PMID: 17016437.
      View in: PubMed
    15. Hoang B, Zhu L, Shi Y, Frost P, Yan H, Sharma S, Sharma S, Goodglick L, Dubinett S, Lichtenstein A. Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood. 2006 Jun 01; 107(11):4484-90. PMID: 16497971.
      View in: PubMed
    16. Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera J, Lichtenstein A. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 2006 Feb 15; 66(4):2305-13. PMID: 16489035.
      View in: PubMed
    17. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther. 2005 Oct; 4(10):1533-40. PMID: 16227402.
      View in: PubMed
    18. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost P, Gibbons J, Lichtenstein A. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 2004 Dec 15; 104(13):4181-7. PMID: 15304393.
      View in: PubMed
    19. Hsu JH, Shi Y, Frost P, Yan H, Hoang B, Sharma S, Gera J, Lichtenstein A. Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene. 2004 Apr 22; 23(19):3368-75. PMID: 15021914.
      View in: PubMed
    20. Frost P, Caliliw R, Belldegrun A, Bonavida B. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. Int J Oncol. 2003 Feb; 22(2):431-7. PMID: 12527945.
      View in: PubMed